Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949906 | 1.00 | MAPT (0.47) | MAPTL3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL8694091 | 0.84 | MEN1 (0.44) | MAPTL3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL8694090 | 0.84 | MEN1 (0.44) | MAPTL3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL5643255 | 0.84 | TDP1 (0.45) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17168992 | 0.84 | CYP19A1 (0.42) | MAPTL3MBTL1KMT2AALDH1A1NPSR1 | |
| SCHEMBL18065654 | 0.83 | MAPT (0.49) | MAPTL3MBTL1MEN1KMT2AMAPK1 | |
| SCHEMBL9003077 | 0.83 | ALDH1A1 (0.46) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL9003082 | 0.83 | ALDH1A1 (0.46) | MAPTL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL10986194 | 0.83 | HCAR2 (0.41) | MAPTL3MBTL1MAPK1ALDH1A1CES1 | |
| SCHEMBL10900631 | 0.83 | ALDH1A1 (0.49) | MAPTL3MBTL1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0326389-B1 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES (JP) | 1996-09-11 | — | — | EP | claimed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | claimed |
| CN-111620870-B | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-111620870-A | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2020-09-04 | — | — | CN | disclosed |
| CN-106414445-B | Compound and application thereof in expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | 蒙特利尔大学 | 2020-07-03 | — | — | CN | disclosed |
| US-10647718-B2 | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | Universitéde Montréal (CA) | 2020-05-12 | — | — | US | disclosed |
| US-10647718-B2 | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | Universitéde Montréal (CA) | 2020-05-12 | — | — | US | disclosed |
| EP-3134409-B1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | UNIV MONTREAL (CA) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134409-B1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | UNIV MONTREAL (CA) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134409-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | Université de Montréal (CA) | 2017-03-01 | — | — | EP | disclosed |
| US-5470982-A | Disubstituted pyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
| EP-0325129-B1 | Disubstituted pyridines | BAYER AG (DE) | 1994-09-07 | — | — | EP | disclosed |
| US-5173495-A | 7-[(2,6-dialkyl-4-furyl or thienyl-pyridyl)]-3,5-di-(dihydroxy-6-enoates) useful for treating circulatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-22 | — | — | US | disclosed |
| US-4968689-A | Certain 2,6-diisopropyl-4-(4-fluoro-phenyl)-3,5-bis-dimethyl-3',5'-dihydroxy-hept-6-enoate-pyridine derivatives useful for treating lipoproteinaemia and arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0325129-A2 | Disubstituted pyridines | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4628109-A | 2-ketosulfonamides and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-12-09 | — | — | US | disclosed |
| EP-0134934-A1 | 2-Keto-sulphon amides and process for their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647718-B2 | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | HPGDS, HCLS1, THPO | MAPT 4638/4885L3MBTL1 1264/4885MEN1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.